<DOC>
	<DOCNO>NCT03067688</DOCNO>
	<brief_summary>Randomized , double-blind , active-controlled , multicenter phase 3 trial evaluate efficacy safety co-administrated temisartan/amlodipine rosuvastatin subject hypertension hyperlipidemia .</brief_summary>
	<brief_title>Clinical Trial Temisartan/Amlodipine &amp; Rosuvastatin Subjects With Hypertension Hyperlipidemia</brief_title>
	<detailed_description>This trial phase 3 study evaluate efficacy safety co-administrated temisartan/amlodipine rosuvastatin subject hypertension hyperlipidemia . In `` Temisartan/Amlodipine/Rosuvastatin '' treatment group , 60 subject assign subject administer `` Temisartan/Amlodipine/Rosuvastatin '' 8 week . In `` Temisartan/Amlodipine '' treatment group , 60 subject assign subject administer `` Temisartan/Amlodipine '' 8 week . In `` Temisartan/Rosuvastatin '' treatment group , 60 subject assign subject administer `` Temisartan/Rosuvastatin '' 8 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Signed informed consent 2 . Subjects hypertension hyperlipidemia 1 . Patients know suspected secondary hypertension 2 . Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>